Hamptons Homebuildi...
Health Care: Drugs
Optimer Pharmaceuticals Inc. (OPTR: NASDAQ)
$14.48 -0.19 | -1.30%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 14.48 |
| 52 Week High | 16.80 |
| 52 Week Low | 8.64 |
| Avg. Daily Vol. (Mil) | 1.00 |
| Beta (3 year) | 0.75 |
| Share Related Items | |
| Mkt Cap (Mil) | 705.48 |
| Shares Out (Mil) | 48.72 |
| Float (Mil) | 30.96 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.70 |
| Current Ratio | 4.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 6.62 |
| Price/Book | 6.71 |
| Price/Cash Flow | -12.50 |
| Per Share Data | |
| Earnings | -1.20 |
| Sales | 2.19 |
| Book Value | 2.16 |
| Cash Flow | -1.16 |
| Business Summary | |
|---|---|
| Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. | |
| General Information | |
| 10110 Sorrento Valley Road
Suite C San Diego, CA 92121 |
|
| www.optimerpharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 281 | |
| CEO: Dr. Henry A. McKinnell,J | |
| Short Interest | |
| Current Month (Mil) | 8.19 |
| Previous Month (Mil) | 8.66 |
| Short Interest Ratio (Days) | 9.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -42.40 |
| Return on Investments | -54.00 |
| Profitability | |
| Gross Margin | 88.70 |
| EBIT Margin | -53.90 |
| Profit Margin | -53.90 |
Portfolios with OPTR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
Latest OPTR Headlines from TheStreet
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tap 05.22.13 | 07:05 am
- 3 Biotech Stocks Spiking With Big Volume 05.13.13 | 02:05 pm
- 3 Biotech Stocks Rising on Big Volume 02.27.13 | 02:02 pm
- 10 Biotech Stocks With A History Of Beating Earning Expectations 01.10.13 | 07:01 pm
- 5 Biotech Stocks Rising on Unusual Volume 11.20.12 | 02:11 pm
- 5 Stocks Moving Higher on Big Volume 09.04.12 | 02:09 pm
- Optimer Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript 07.31.12 | 10:07 pm
- Optimer Pharmaceuticals Inc. Stock Downgraded (OPTR) 05.17.12 | 05:05 am
- 5 Earnings Stocks Poised to Pop 05.09.12 | 10:05 am
- 7 Stocks Spiking on Unusual Volume 04.25.12 | 01:04 pm
Press Releases for OPTR
- Optimer Pharmaceuticals Appoints Eric Sirota As Chief Operating Officer - PR Newswire 05.13.13 | 04:05 pm
- Optimer Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results - PR Newswire 05.02.13 | 08:05 am
- DIFICID® (fidaxomicin) Tablets Approved In Australia - PR Newswire 04.26.13 | 08:04 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 03.15.13 | 08:03 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 02.27.13 | 08:02 am
- Optimer Pharmaceuticals' Board Of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer - PR Newswire 02.27.13 | 08:02 am
- New Analysis Shows Age Has A Significant Effect On Outcomes In Patients Being Treated For Clostridium Difficile Infection (CDI) - PR Newswire 02.14.13 | 08:02 am
- Optimer Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year 2012 Financial Results - PR Newswire 02.07.13 | 08:02 am
- Optimer Pharmaceuticals To Present At Leerink Swann Global Healthcare Conference - PR Newswire 02.07.13 | 08:02 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 02.01.13 | 08:02 am
Partner Headlines for OPTR
- Narrower Loss at Optimer - Analyst Blog - Zacks 11.02.12 | 05:11 pm
- Pipeline Progress at Cubist Pharma - Analyst Blog - Zacks 11.01.12 | 06:11 pm
- Earnings Preview: Cubist Pharma - Analyst Blog - Zacks 10.17.12 | 09:10 am
- Optimer Pharma to Sell Optimer Bio Stake - Analyst Blog - Zacks 10.09.12 | 07:10 pm
- UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals to Perform on Near-Term Outlook - Benzinga 10.09.12 | 01:10 pm
- UPDATE: Morgan Stanley Initiates Optimer Pharmaceuticals at Underweight on Risk/Reward - Benzinga 10.04.12 | 01:10 pm
- How one bull is playing Optimer Pharma - NASDAQ 09.11.12 | 09:09 am
- Optimer's Dificid OK'd in Canada - Analyst Blog - Zacks 07.09.12 | 07:07 pm
- Optimer Earns Milestone Payment - Analyst Blog - Zacks 06.08.12 | 04:06 pm
- UPDATE: Ladenburg Thalmann Maintains Buy Rating, Raises PT for Optimer Pharmaceuticals - Benzinga 05.11.12 | 09:05 am
